NEUROMARK system, which includes biofeedback monitoring features and advanced algorithmic controls, is a novel multi-point nerve disruption treatment for chronic rhinitis
NEUROMARK system is a novel multi-point nerve disruption treatment for chronic rhinitis. (Credit: Luisella Planeta Leoni from Pixabay)
Neurent Medical has secured approval from the US Food and Drug Administration (FDA) for its NEUROMARK Rhinitis Neurolysis Therapy (RNT).
The in-office treatment allows clinicians to disrupt posterior nasal nerves by creating lesions in patients with chronic rhinitis.
NEUROMARK system, which includes biofeedback monitoring features and advanced algorithmic controls, is a novel multi-point nerve disruption treatment for chronic rhinitis.
Neurent Medical scientific advisor Dr Marc Dubin said: “The FDA clearance of NEUROMARK RNT means otolaryngologists can now offer precise care to patients with chronic rhinitis, while avoiding the trial and error that often goes into treating this condition.”
With a high degree of anatomical precision, safety, and patient comfort, the system allows physician to simultaneously disrupt multiple nerve branches, the company said.
To access and disrupt hard-to-reach posterior nasal nerves in a single placement, NEUROMARK RNT features a unique flexible electrode array geometry.
According to the company, one in four Americans suffer from chronic rhinitis, which may cause persistent congestion, rhinorrhea (runny nose), sneezing and nasal itching due to inflammation and swelling of the mucosal membrane in the nose.
Neurent Medical CEO Brian Shields said: “NEUROMARK addresses the limitations of other treatments and uses advanced technology to do so safely, gently and with ease. The market need is immense and underserved, and we are excited to bring our initial product offering to the market, providing symptom relief to as many patients as possible.
“We are equally as excited to continue our product pipeline development to address other sino-nasal inflammatory conditions and realize the full potential of the NEUROMARK platform.”
Headquartered in Galway, Ireland, Neurent Medical is engaged in developing innovative treatments for chronic inflammatory sino-nasal diseases by targeting and disrupting hyperactive autonomic nerves.